The story of Viagra, formerly marketed by copyright, presents a complex case study for investors considering the pharmaceutical arena . Despite its early success and generation of billions in earnings , the intellectual property lapse has opened the door for generic medications, greatly reducing profit opportunities. This transition raises concerns